168 related articles for article (PubMed ID: 31257604)
1. Comparison of Neutropenia Associated with Ceftaroline or Ceftriaxone in Patients Receiving at Least 7 Days of Therapy for Severe Infections.
Veve MP; Stuart M; Davis SL
Pharmacotherapy; 2019 Aug; 39(8):809-815. PubMed ID: 31257604
[TBL] [Abstract][Full Text] [Related]
2. Neutropenia Associated with Long-Term Ceftaroline Use.
LaVie KW; Anderson SW; O'Neal HR; Rice TW; Saavedra TC; O'Neal CS
Antimicrob Agents Chemother; 2016 Jan; 60(1):264-9. PubMed ID: 26503657
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline.
Turner RB; Wilson DE; Saedi-Kwon H; Chang E; Won R; Chan D; Schwartz J
J Antimicrob Chemother; 2018 Mar; 73(3):772-778. PubMed ID: 29237024
[TBL] [Abstract][Full Text] [Related]
4. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
Rank DR; Friedland HD; Laudano JB
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570
[TBL] [Abstract][Full Text] [Related]
5. Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
Zasowski EJ; Trinh TD; Claeys KC; Casapao AM; Sabagha N; Lagnf AM; Klinker KP; Davis SL; Rybak MJ
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895012
[TBL] [Abstract][Full Text] [Related]
6. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.
Cannavino CR; Nemeth A; Korczowski B; Bradley JS; O'Neal T; Jandourek A; Friedland HD; Kaplan SL
Pediatr Infect Dis J; 2016 Jul; 35(7):752-9. PubMed ID: 27093162
[TBL] [Abstract][Full Text] [Related]
7. A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia.
Blumer JL; Ghonghadze T; Cannavino C; O'Neal T; Jandourek A; Friedland HD; Bradley JS
Pediatr Infect Dis J; 2016 Jul; 35(7):760-6. PubMed ID: 27078119
[TBL] [Abstract][Full Text] [Related]
8. High incidence of neutropenia in patients with prolonged ceftaroline exposure.
Furtek KJ; Kubiak DW; Barra M; Varughese CA; Ashbaugh CD; Koo S
J Antimicrob Chemother; 2016 Jul; 71(7):2010-3. PubMed ID: 27076105
[TBL] [Abstract][Full Text] [Related]
9. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients.
Lin JC; Aung G; Thomas A; Jahng M; Johns S; Fierer J
J Infect Chemother; 2013 Feb; 19(1):42-9. PubMed ID: 22797874
[TBL] [Abstract][Full Text] [Related]
10. Ceftaroline - a cause for neutropenia.
Rimawi RH; Frenkel A; Cook PP
J Clin Pharm Ther; 2013 Aug; 38(4):330-2. PubMed ID: 23590618
[TBL] [Abstract][Full Text] [Related]
11. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley I; Thye D
Clin Infect Dis; 2010 Dec; 51(12):1395-405. PubMed ID: 21067350
[TBL] [Abstract][Full Text] [Related]
12. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
[TBL] [Abstract][Full Text] [Related]
13. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
[TBL] [Abstract][Full Text] [Related]
14. Rate and Incidence of Adverse Reactions Associated With Ceftaroline Exposure: Importance of Cutaneous Manifestations.
Jansen JW; Moenster RP
Ann Pharmacother; 2018 Mar; 52(3):235-239. PubMed ID: 28980484
[TBL] [Abstract][Full Text] [Related]
15. Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy.
DiMondi VP; Drew RH; Chen LF
Expert Rev Anti Infect Ther; 2011 Aug; 9(8):567-72. PubMed ID: 21819323
[TBL] [Abstract][Full Text] [Related]
16. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy.
Ho TT; Cadena J; Childs LM; Gonzalez-Velez M; Lewis JS
J Antimicrob Chemother; 2012 May; 67(5):1267-70. PubMed ID: 22311935
[TBL] [Abstract][Full Text] [Related]
17. A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline.
Yam FK; Kwan BK
Am J Health Syst Pharm; 2014 Sep; 71(17):1457-61. PubMed ID: 25147169
[TBL] [Abstract][Full Text] [Related]
18. Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience.
Lipsky BA; Cannon CM; Ramani A; Jandourek A; Calmaggi A; Friedland HD; Goldstein EJ
Diabetes Metab Res Rev; 2015 May; 31(4):395-401. PubMed ID: 25417910
[TBL] [Abstract][Full Text] [Related]
19. Ceftaroline as Salvage Monotherapy for Persistent MRSA Bacteremia.
Burnett YJ; Echevarria K; Traugott KA
Ann Pharmacother; 2016 Dec; 50(12):1051-1059. PubMed ID: 27520326
[TBL] [Abstract][Full Text] [Related]
20. Short versus long duration of ceftaroline combination therapy and outcomes in persistent or high-grade MRSA bacteremia: A retrospective single-center study.
Cabanilla MG; Bernauer ML; Atallah LM; Briski MJ; Koury J; Thompson CM; Rodriguez CN; Jakeman B; Byrd TF
PLoS One; 2024; 19(5):e0304103. PubMed ID: 38768130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
